Table 1 Demographic and perioperative data
Group CEI (n = 40) | Group PIEB (n = 44) | p-value | |
|---|---|---|---|
Age, y | 58 ± 16 | 63 ± 12 | 0.09 |
Sex, (M/F) | 9/31 | 15/29 | 0.24 |
Weight, kg | 80 ± 21 | 79 ± 20 | 0.96 |
Height, cm | 167 ± 8 | 168 ± 9 | 0.61 |
BMI, kg/m2 | 29 ± 7 | 28 ± 7 | 0.81 |
ASA status I/II/III | 0/23/17 | 1/28/15) | 0.37 |
Length of hospital stay, d | 14 (10–18) | 12 (10–16) | 0.53 |
Type of surgery (colonic/pancreatic/gynaecological) | 12/09/19 | 14/10/20 | 0.84 |
Length of surgery, min | 205 (171–329) | 173(135–253) | 0.06 |
Epidural insertion height (lower spinal segment) | Th10 (Th9-Th11) | Th10 (Th9-Th11) | 0.60 |
Epidural catheter performance time, min | 12(8–17) | 10(7–12) | 0.14 |
Length of epidural catheter therapy, d | 5 (5–7) | 5 (5–6) | 0.33 |
MAP initial (MAP1), mmHg | 107 (91–123) | 103 (93–114) | 0.46 |
MAP at initial ropivacaine administration (MAP 2), mmHg | 97 (90–116) | 100 (89–113) | 0.81 |
MAP 15min after initial ropivacaine administration (MAP 3), mmHg | 88 (76–97) | 86 (78–98) | 0.94 |
Sufentanil for EDA placement, μg | 0 (0–10) | 0 (0–5) | 0.24 |
Metamizole intraoperative, g | 1.5 (1–1.5) | 1.5 (1.5–1.5) | 0.76 |
Metamizole d0, g | 2 (1–3.5) | 2 (1–3) | 0.73 |
Metamizole d1, g | 4 (4–4) | 4 (3–4) | 0.22 |
Metamizole d2, g | 4 (4–4) | 4 (4–4) | 0.41 |
Ibuprofen d0, g | 0.8 (0.4–0.8) | 0.8 (0.6–0.8) | 0.66 |
Ibuprofen d1, g | 1.2 (0.8–1.4) | 1.2 (0.6–1.2) | 0.83 |
Ibuprofen d2, g | 1.2 (1.2–1.6) | 1.2 (1.2–1.8) | 0.33 |
Opioids d0, % (yes/no) | 30 (12/28) | 36.4 (16/28) | 0.54 |
Opioids d1, % (yes/no) | 45 (18/22) | 40.1 (18/26) | 0.71 |
Opioids d2, % (yes/no) | 67.5 (27/13) | 50 (22/22) | 0.11 |
Opiods d0–2, % (yes/no) | 75 (30/10) | 66 (29/15) | 0.37 |